783 related articles for article (PubMed ID: 12214462)
21. Low-risk gestational trophoblastic neoplasia and methotrexate resistance: predictors of response to treatment with actinomycin D and need for combination chemotherapy.
Growdon WB; Wolfberg AJ; Goldstein DP; Feltmate CM; Chinchilla ME; Lieberman ES; Berkowitz RS
J Reprod Med; 2010; 55(7-8):279-84. PubMed ID: 20795339
[TBL] [Abstract][Full Text] [Related]
22. Plasma methotrexate levels in patients receiving etoposide, methotrexate, actinomycin, cyclophosphamide, and vincristine (EMA-CO) chemotherapy for trophoblastic neoplasia.
Kohorn EI
Gynecol Oncol; 1993 Sep; 50(3):300-4. PubMed ID: 8406191
[TBL] [Abstract][Full Text] [Related]
23. Methotrexate monotherapy for high-risk gestational trophoblastic neoplasia after therapy with etoposide, methotrexate, and dactinomycin: a case report.
Taran A; Ignatov A; Smith B; Bischoff J; Costa SD
Am J Obstet Gynecol; 2008 Nov; 199(5):e6-8. PubMed ID: 18984073
[TBL] [Abstract][Full Text] [Related]
24. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors.
Newlands ES; Mulholland PJ; Holden L; Seckl MJ; Rustin GJ
J Clin Oncol; 2000 Feb; 18(4):854-9. PubMed ID: 10673528
[TBL] [Abstract][Full Text] [Related]
25. Management of high-risk hydatidiform mole and persistent gestational trophoblastic neoplasia: the Korean experience.
Kim SJ; Na YJ; Jung SG; Kim CJ; Bae SN; Lee C
J Reprod Med; 2007 Sep; 52(9):819-30. PubMed ID: 17939600
[TBL] [Abstract][Full Text] [Related]
26. Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors.
Matsui H; Suzuka K; Iitsuka Y; Seki K; Sekiya S
Gynecol Oncol; 2000 Jul; 78(1):28-31. PubMed ID: 10873405
[TBL] [Abstract][Full Text] [Related]
27. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000.
McNeish IA; Strickland S; Holden L; Rustin GJ; Foskett M; Seckl MJ; Newlands ES
J Clin Oncol; 2002 Apr; 20(7):1838-44. PubMed ID: 11919242
[TBL] [Abstract][Full Text] [Related]
28. Successful salvage therapy of resistant gestational trophoblastic disease with etoposide, methotrexate, actinomycin-D, etoposide, cisplatin (EMA/EP).
Bilgin T; Ozan H; Ozuysal S; Ozkan L
Arch Gynecol Obstet; 2004 Jan; 269(2):159-60. PubMed ID: 14648186
[TBL] [Abstract][Full Text] [Related]
29. Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease.
Dobson LS; Lorigan PC; Coleman RE; Hancock BW
Br J Cancer; 2000 May; 82(9):1547-52. PubMed ID: 10789722
[TBL] [Abstract][Full Text] [Related]
30. Development of single-agent chemotherapy regimens for gestational trophoblastic disease.
Homesley HD
J Reprod Med; 1994 Mar; 39(3):185-92. PubMed ID: 7518517
[TBL] [Abstract][Full Text] [Related]
31. [Etopside, methotrexate, kengshengmycin/etopside, cisplatin chemotherapy for chemorefractory gestational trophoblastic tumour].
Xiang Y; Wan XR; Sun ZJ; Yang XY
Zhonghua Fu Chan Ke Za Zhi; 2005 Feb; 40(2):79-82. PubMed ID: 15840283
[TBL] [Abstract][Full Text] [Related]
32. Management of gestational trophoblastic diseases: subsequent pregnancy experience.
Berkowitz RS; Tuncer ZS; Bernstein MR; Goldstein DP
Semin Oncol; 2000 Dec; 27(6):678-85. PubMed ID: 11130475
[TBL] [Abstract][Full Text] [Related]
33. Risk of recurrent hydatidiform mole and subsequent pregnancy outcome following complete or partial hydatidiform molar pregnancy.
Sebire NJ; Fisher RA; Foskett M; Rees H; Seckl MJ; Newlands ES
BJOG; 2003 Jan; 110(1):22-6. PubMed ID: 12504931
[TBL] [Abstract][Full Text] [Related]
34. [Chemotherapy of high-risk trophoblastic neoplasia].
Kawashima Y; Maeda M; Sugimura M
Gan To Kagaku Ryoho; 1987 Sep; 14(9):2658-66. PubMed ID: 2820310
[TBL] [Abstract][Full Text] [Related]
35. Role of surgery in the management of high-risk gestational trophoblastic neoplasia.
Lurain JR; Singh DK; Schink JC
J Reprod Med; 2006 Oct; 51(10):773-6. PubMed ID: 17086805
[TBL] [Abstract][Full Text] [Related]
36. The risk of persistent trophoblastic disease after hydatidiform mole classified by morphology and ploidy.
Niemann I; Hansen ES; Sunde L
Gynecol Oncol; 2007 Feb; 104(2):411-5. PubMed ID: 17011616
[TBL] [Abstract][Full Text] [Related]
37. Management of high-risk gestational trophoblastic disease.
Lurain JR
J Reprod Med; 1998 Jan; 43(1):44-52. PubMed ID: 9475149
[TBL] [Abstract][Full Text] [Related]
38. Persistent trophoblast disease following partial molar pregnancy.
Wielsma S; Kerkmeijer L; Bekkers R; Pyman J; Tan J; Quinn M
Aust N Z J Obstet Gynaecol; 2006 Apr; 46(2):119-23. PubMed ID: 16638033
[TBL] [Abstract][Full Text] [Related]
39. Gestational trophoblastic disease. Subsequent pregnancy outcome, including repeat molar pregnancy.
Berkowitz RS; Im SS; Bernstein MR; Goldstein DP
J Reprod Med; 1998 Jan; 43(1):81-6. PubMed ID: 9475154
[TBL] [Abstract][Full Text] [Related]
40. Gestational trophoblastic disease: a 21-year review of the clinical experience at an Argentinean public hospital.
Bianconi MI; Otero S; Moscheni O; Alvarez L; Storino C; Jankilevich G
J Reprod Med; 2012; 57(7-8):341-9. PubMed ID: 22838252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
